BioCryst Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Great. Good afternoon, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing the Health Care Conference today with BioCryst. I'm joined on stage by the company's CEO, Jon Stonehouse. He's going to give a presentation and then we're going to go into Q&A right afterwards. If you have a question in the room, just raise your hand and we'll bring you a microphone or alternatively, you can submit questions to the portal. Without me, pass over to John.
Great. Thank you, Jess. Good afternoon. Good evening to those of you on the webcast and thank you for inviting us again to your healthcare conference. I'm going to be making some forward-looking statements. Those statements have risks. The risk factors can be found in our most recent filings, which can be found on our website listed at the bottom of slide 2, we are uniquely positioned to create sustainable value at BioCryst and let me explain why? First, we have a growing marketed product and Orladeyo that's on a path to 1
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
